Tempus and Gilead expanded their data partnership, giving Gilead broader access to Tempus’ multimodal real-world cancer datasets and the Tempus AI platform. The update builds on an existing deal in which Gilead could use de-identified patient data for trial design and biomarker strategy. Under the expanded collaboration, Gilead will access more multimodal data across indications and use Tempus’ Lens analytics environment, which integrates tumor-normal DNA/RNA data and H&E slide information. Tempus said Lens can apply cohort filtering, simulate clinical trials, and visualize datasets, and it includes a large language model integrated into the platform. Tempus framed the expanded access as enabling “signal in the noise” searches across very large datasets, and the partnership adds another example of pharma-company RWD strategy focused on AI-driven cohorting and development decisions.